Scott Joseph Antonia

Journal Article ESMO Open · February 2024 INTRODUCTION: We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced ... Full text Link to item Cite

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Journal Article Lung Cancer · May 2022 OBJECTIVE: In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs). MATERIALS AND METHODS: Patients (N = ... Full text Link to item Cite

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

Journal Article Lancet Oncol · October 2019 BACKGROUND: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cance ... Full text Link to item Cite

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.

Journal Article N Engl J Med · March 7, 2019 Full text Link to item Cite